文献速递肝病消化道肿瘤与早癌

MicroRNA-15a/16-1通过阻断库普弗细胞与调节性T细胞间通讯预防肝细胞癌

MicroRNA-15a/16-1 Prevents Hepatocellular Carcinoma by Disrupting the Communication Between Kupffer Cells and Regulatory T Cells.
PubMed 文献 · Gastroenterology · 2021-10-19

该研究在AKT/Ras或c-Myc诱导的肝细胞癌(HCC)小鼠模型中,利用Sleeping Beauty转座子系统递送microRNA-15a/16-1。结果显示HCC损害库普弗细胞(KC)中microRNA-15a/16-1的生成,而递送该microRNA可完全预防HCC并促使肿瘤消退,机制为抑制NF-κB激活的Ccl22转录,减少CCL22介导的Treg趋化。

要点

  • HCC小鼠KC中microRNA-15a/16-1生成受损,递送该microRNA可完全预防HCC。
  • 治疗性递送microRNA-15a/16-1促进两种HCC模型肿瘤消退并减少Treg富集。
  • 机制为抑制NF-κB激活的Ccl22转录,阻断CCL22-CCR4介导的Treg趋化。

核心结论

  • MicroRNA-15a/16-1通过破坏KC与Treg间CCL22介导的通讯来减轻免疫抑制,是潜在的HCC免疫治疗手段。

研究设计与样本

  • FVB/NJ小鼠经流体动力学注射AKT/Ras或c-Myc及Sleeping Beauty转座子诱导HCC。
  • 利用Sleeping Beauty系统将microRNA-15a/16-1递送至小鼠肝脏。
  • 采用流式细胞术和免疫染色检测免疫系统变化。

主要发现

  • AKT/Ras或c-Myc注射导致肝脏Treg富集、细胞毒性T细胞(CTL)减少并发生HCC。
  • AKT/Ras和c-Myc小鼠的KC中microRNA-15a/16-1生成受损。
  • 递送microRNA-15a/16-1完全预防AKT/Ras和c-Myc小鼠HCC,而对照组小鼠100%死于HCC。
  • 治疗性递送microRNA-15a/16-1促进两种模型HCC消退,减少肝脏Treg富集并增加肝脏CTL。
  • AKT/Ras和c-Myc小鼠血清CCL22及KC中Ccl22转录显著增加。

关键数值与推荐

  • microRNA-15a/16-1通过抑制激活Ccl22转录的NF-κB来阻止KC过度产生CCL22。
  • microRNA-15a/16-1通过减少CCL22与Treg上CCR4结合来削弱Treg趋化。
  • 破坏microRNA-15a/16-1与NF-κB的相互作用会削弱其预防肝脏Treg聚集和HCC的能力。
  • 清除CD8+ T细胞并额外给予CCL22可恢复被microRNA-15a/16完全预防的HCC生长。

临床怎么用

  • 该microRNA策略在小鼠模型中展示预防和治疗HCC的潜力,支持其作为HCC免疫治疗的进一步转化研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Hepatocellular carcinoma (HCC) is characterized by intratumoral accumulation of regulatory T cells (Tregs), which suppresses antitumor immunity. This study was designed to investigate how microRNAs regulate immunosuppression in HCC. METHODS: FVB/NJ mice were hydrodynamically injected with AKT/Ras or c-Myc and Sleeping Beauty transposon to induce HCC. The Sleeping Beauty system was used to deliver microRNA-15a/16-1 into livers of mice. Flow cytometry and immunostaining were used to determine changes in the immune system. RESULTS: Hydrodynamic injection of AKT/Ras or c-Myc into mice resulted in hepatic enrichment of Tregs and reduced cytotoxic T cells (CTLs) and HCC development. HCC impaired microRNA-15a/16-1 biogenesis in Kupffer cells (KCs) of AKT/Ras and c-Myc mice. Hydrodynamic injection of microRNA-15a/16-1 fully prevented HCC in AKT/Ras and c-Myc mice, while 100% of control mice died of HCC. Therapeutically, microRNA-15a/16-1 promoted a regression of HCC in both mouse models, impaired hepatic enrichment of Tregs, and increased hepatic CTLs. Mechanistically, a significant increase was observed in serum C-C motif chemokine 22 (CCL22) and transcription of Ccl22 in KCs of AKT/Ras and c-Myc mice. MicroRNA-15a/16-1 prevented KCs from overproducing CCL22 by inhibiting nuclear factor-κB that activates transcription of Ccl22. By reducing CCL22 binding to C-C chemokine receptor type 4 on Tregs, microRNA-15a/16-1 impaired Treg chemotaxis. Disrupting the interaction between microRNA-15a/16-1 and nuclear factor-κB impaired the ability of microRNA-15a/16-1 to prevent hepatic Treg accumulation and HCC. Depletion of cluster of differentiation 8+ T cells and additional treatment of CCL22 recovered growth of HCC that was fully prevented by microRNA-15a/16. CONCLUSIONS: MicroRNA-15a/16-1 attenuates immunosuppression by disrupting CCL22-mediated communication between KCs and Tregs. MicroRNA-15a/16-1 represents a potential immunotherapy against HCC.

来源:Gastroenterology,查看原文。版权归原作者所有。

引用

  1. Liu N, Chang CW, Steer CJ, et al. MicroRNA-15a/16-1 Prevents Hepatocellular Carcinoma by Disrupting the Communication Between Kupffer Cells and Regulatory T Cells. Gastroenterology. 2021. PMID: 34678217. doi:10.1053/j.gastro.2021.10.015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。